Based on the provided paper content, here are the answers to the questions.

"""
Question: 1101

Evidence: In this study, we retrospectively evaluated the diversity of HIV-1 subtypes and the TDRM prevalence in 135 treatment-naïve HIV-1 vertically infected children and adolescents born in between 1993 and 2012. All the partial HIV-1 pol sequences generated in this study were...submitted to the NCBI GenBank database. The GenBank database accession numbers for the HIV-1 pol sequences described in this study are OL624883-OL625013.

Rationale: The paper explicitly states that it is presenting a retrospective study of 135 treatment-naïve children and adolescents, and it provides the GenBank accession numbers for the sequences generated in this study, confirming that the data is new and previously unpublished.

Answer: Yes
"""

"""
Question: 1102

Evidence: All the partial HIV-1 pol sequences generated in this study were evaluated by the HIV-1 sequence quality tool from Los Alamos HIV sequence database...and submitted to the NCBI GenBank database. The GenBank database accession numbers for the HIV-1 pol sequences described in this study are OL624883-OL625013.

Rationale: The paper directly states that it generated and submitted HIV-1 pol sequences to GenBank, confirming the reporting of HIV sequences.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper content does not contain any mention of in vitro passage experiments.

Rationale: A thorough review of the paper's abstract, introduction, methods, results, and discussion sections finds no reference to in vitro passage experiments. The study is focused on clinical samples and sequence analysis.

Answer: No
"""

"""
Question: 1104

Evidence: The paper content does not contain any mention of in vitro antiretroviral susceptibility testing or data.

Rationale: The methods section describes genotypic resistance testing and analysis using the Stanford HIVdb Program to predict drug susceptibility, but it does not report any laboratory-based phenotypic susceptibility assays or their results (e.g., IC50 values).

Answer: No
"""

"""
Question: 2101

Evidence: All the partial HIV-1 pol sequences generated in this study were...submitted to the NCBI GenBank database. The GenBank database accession numbers for the HIV-1 pol sequences described in this study are OL624883-OL625013.

Rationale: The paper explicitly provides the GenBank accession numbers for the HIV-1 sequences generated from the study participants.

Answer: Yes
"""

"""
Question: 2102

Evidence: All the partial HIV-1 pol sequences generated in this study were...submitted to the NCBI GenBank database. The GenBank database accession numbers for the HIV-1 pol sequences described in this study are OL624883-OL625013.

Rationale: The paper only reports GenBank accession numbers for sequences obtained from the clinical isolates of the pediatric cohort in this study. There is no mention of accession numbers for laboratory HIV isolates.

Answer: Yes
"""

"""
Question: 2103

Evidence: The GenBank database accession numbers for the HIV-1 pol sequences described in this study are OL624883-OL625013.

Rationale: This sentence directly provides the range of GenBank accession numbers reported in the paper.

Answer: OL624883-OL625013
"""

"""
Question: 2202

Evidence: Table 2 summarizes nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PI) transmitted drug resistance mutations, HIV-1 subtype and resistance profiles level. For example, sample PC_19 had mutations M41L, T215Y, and K103N.

Rationale: Table 2 lists specific mutations (e.g., M41L, T215Y, K103N) for individual sequenced HIV isolates (e.g., PC_19, 09CR023).

Answer: Yes
"""

"""
Question: 2301

Evidence: The human immunodeficiency virus type 1 (HIV-1) can be transmitted via parenteral, sexual, or vertical exposure routes.

Rationale: The paper exclusively mentions and studies Human Immunodeficiency Virus Type 1 (HIV-1). There is no mention of HIV-2.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: The majority HIV-1 pol sequences (87%) were classified as pure HIV-1 subtypes (77% subtype B, 9% subtype F1 and 1.5% subtype C), while 13% of sequences were classified as recombinants (CRF45_cpx, n = 4; CRF28/29_BF1, n = 2; CRF02_AG, n = 1; CRF40_BF1, n = 1, CRF99_BF1, n = 1, URF_BF1, n = 8).

Rationale: This section from the results provides a detailed breakdown of the subtypes of the sequenced viruses.

Answer: Subtype B, Subtype F1, Subtype C, and recombinants including CRF45_cpx, CRF28/29_BF1, CRF02_AG, CRF40_BF1, CRF99_BF1, and URF_BF1.
"""

"""
Question: 2303

Evidence: We retrospectively evaluated the HIV-1 pol (protease/reverse transcriptase-PR/RT) sequences obtained from treatment-naïve HIV-1-positive vertically infected children.

Rationale: The paper explicitly states that the gene regions sequenced were the protease (PR) and reverse transcriptase (RT) regions of the HIV-1 pol gene.

Answer: pol (protease and reverse transcriptase)
"""

"""
Question: 2304

Evidence: We retrospectively evaluated the HIV-1 pol (protease/reverse transcriptase-PR/RT) sequences obtained from treatment-naïve HIV-1-positive vertically infected children. The phylogenetic analysis of the HIV-1 pol PR/RT regions of 135 treatment-naïve children and adolescents showed that most sequences (87%, 118/135) were classified as pure subtypes.

Rationale: The entire study is based on the analysis of HIV-1 pol sequences, as stated in the abstract, methods, and results.

Answer: Yes
"""

"""
Question: 2401

Evidence: One hundred thirty-five treatment-naïve HIV-1 infected children and adolescents...attended in clinics of the Public Health System in the state of Rio de Janeiro.

Rationale: The paper clearly states that all study subjects were from the state of Rio de Janeiro, Brazil.

Answer: Rio de Janeiro, Brazil
"""

"""
Question: 2402

Evidence: These children were assessed in either 2001–2007 or 2008–2012 when they were 0 to 17 years old.

Rationale: The paper defines two clear time periods during which the samples were obtained for sequencing.

Answer: 2001-2007 and 2008-2012
"""

"""
Question: 2502

Evidence: In the 2001–2007 period, the entire protease (PR) and reverse transcriptase (RT) gene sequences were obtained...using the ViroSeq™ HIV Genotyping System...The purified PCR products were sequenced with an ABI PRISM 3100xl Genetic Analyzer. In the 2008–2012 period, HIV-1 PR and RT nucleotide sequences were generated using the TRUGENE ® HIV-1 Genotyping Assay.

Rationale: The methods describe the use of ViroSeq and TRUGENE genotyping assays, which are both based on Sanger sequencing technology, and the use of an ABI PRISM 3100xl Genetic Analyzer, a Sanger sequencer.

Answer: Yes
"""

"""
Question: 2503

Evidence: The paper content does not contain any mention of Next-Generation Sequencing (NGS) technologies.

Rationale: The sequencing methods described (ViroSeq and TRUGENE kits with ABI PRISM analyzer) are exclusively Sanger-based. No NGS platforms or terminologies are mentioned.

Answer: No
"""

"""
Question: 2504

Evidence: The paper content does not contain any mention of cloning samples prior to sequencing.

Rationale: The described methods involve direct PCR amplification and sequencing from plasma samples without a cloning step.

Answer: No
"""

"""
Question: 2505

Evidence: The paper content does not contain any mention of single genome sequencing.

Rationale: The methods section describes bulk PCR amplification and sequencing, not single genome sequencing.

Answer: No
"""

"""
Question: 2506

Evidence: The paper content does not contain any mention of molecular cloning.

Rationale: The described sequencing methodology does not include a molecular cloning step.

Answer: No
"""

"""
Question: 2601

Evidence: In the 2001–2007 period, the entire protease (PR) and reverse transcriptase (RT) gene sequences were obtained from plasma samples.

Rationale: The paper explicitly states that sequences were obtained from plasma samples.

Answer: Yes
"""

"""
Question: 2602

Evidence: The paper content does not contain any mention of sequencing from PBMCs.

Rationale: The methods section only describes sequencing from plasma. PBMCs are not mentioned.

Answer: No
"""

"""
Question: 2603

Evidence: In the 2001–2007 period...sequences obtained from 38 HIV-1 infected children...from plasma samples. 2008–2012, 97 HIV-1 pol sequences from children and adolescents.

Rationale: The total number of sequences reported is 135 (38 + 97), all of which were obtained from plasma as per the methods description.

Answer: 135
"""

"""
Question: 2604

Evidence: The paper content does not contain any mention of sequencing from PBMCs.

Rationale: As PBMC sequencing was not performed, the number is zero.

Answer: 0
"""

"""
Question: 2605

Evidence: The entire protease (PR) and reverse transcriptase (RT) gene sequences were obtained from plasma samples from HIV-1 positive individuals. The overall median HIV-1 plasma viral load observed in this period was of 4.69 log10 copies/mL.

Rationale: Sequencing from plasma and the reported high viral loads indicate that sequences were obtained from individuals with active HIV replication.

Answer: Yes
"""

"""
Question: 2606

Evidence: The paper content does not contain any mention of sequencing from proviral DNA.

Rationale: The methods and results sections only discuss sequencing from plasma RNA, not from the proviral DNA reservoir in cells.

Answer: No
"""

"""
Question: 2701

Evidence: One hundred thirty-five treatment-naïve HIV-1 infected children and adolescents...These children were assessed in either 2001–2007 or 2008–2012 when they were 0 to 17 years old.

Rationale: The paper's entire cohort consists of children and adolescents aged 0 to 17 years.

Answer: Yes
"""

"""
Question: 2702

Evidence: The paper content does not contain any mention of a clinical trial.

Rationale: The study is described as a retrospective evaluation of a convenience sample from a database, not as a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: The paper content does not contain any mention of a clinical trial.

Rationale: Since no individuals are reported to be in a clinical trial, it follows that not all of them were.

Answer: No
"""

"""
Question: 3101

Evidence: One hundred thirty-five treatment-naïve HIV-1 infected children and adolescents were evaluated during the timeframe of this study (2001 to 2012).

Rationale: This sentence explicitly states the total number of individuals who had samples obtained for HIV sequencing.

Answer: 135
"""

"""
Question: 3102

Evidence: One hundred thirty-five treatment-naïve HIV-1 infected children and adolescents were evaluated...we analyzed a convenience sampling of 135 HIV-1 pol PR/RT sequences.

Rationale: The paper states that 135 individuals were evaluated and that 135 sequences were analyzed, indicating that all individuals underwent sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: One hundred thirty-five treatment-naïve HIV-1 infected children and adolescents were evaluated.

Rationale: The term "treatment-naïve" is used repeatedly to describe the entire cohort, confirming that all sequences are from ART-naive individuals.

Answer: Yes
"""

"""
Question: 4102

Evidence: The paper content does not contain any mention of individuals who had previously received ARV drugs.

Rationale: The cohort is explicitly and consistently described as "treatment-naïve".

Answer: No
"""

"""
Question: 4103

Evidence: One hundred thirty-five treatment-naïve HIV-1 infected children and adolescents were evaluated.

Rationale: The paper only reports sequences from ART-naive individuals. There is no group of ART-experienced individuals.

Answer: No
"""

"""
Question: 4104

Evidence: One hundred thirty-five treatment-naïve HIV-1 infected children and adolescents were evaluated.

Rationale: This sentence confirms that all 135 samples were from ART-naive individuals.

Answer: 135
"""

"""
Question: 4105

Evidence: The paper content does not contain a complete ART history for the individuals.

Rationale: The paper states the individuals were "treatment-naïve" at the time of sampling, but it does not provide detailed historical ART records for each individual, such as whether mothers received prophylaxis.

Answer: No
"""

"""
Question: 4201

Evidence: The overall prevalence of TDRM was 14% (19/135), conferring resistance to the nucleoside reverse transcriptase inhibitors (NRTI, 13/135–9.6%), non-nucleoside reverse transcriptase inhibitors (NNRTI, 8/135–5.9%), and protease inhibitors (PI, 2/135–1.5%).

Rationale: The paper directly reports the prevalence of Transmitted Drug Resistance Mutations (TDRM) in the cohort.

Answer: Yes
"""

"""
Question: 4202

Evidence: The overall prevalence of TDRM was 14% (19/135). According to the CPR analysis, the overall TDRM prevalence in the 2001–2007-time interval was 24% (9/38)...In the 2008–2012 period, the overall TDRM prevalence was 10% (10/97).

Rationale: Since all individuals were treatment-naïve, the reported TDRM prevalence is equivalent to pretreatment HIV drug resistance.

Answer: Yes
"""

"""
Question: 4301

Evidence: The paper content does not contain information on which drug classes were received by the individuals in the study.

Rationale: The individuals in the study are explicitly "treatment-naïve," meaning they had not received any ART at the time of sampling.

Answer: NA
"""

"""
Question: 4302

Evidence: The paper content does not contain information on individuals who received integrase inhibitors.

Rationale: The study focuses on treatment-naïve individuals and on resistance to NRTIs, NNRTIs, and PIs. Integrase inhibitors are not mentioned.

Answer: No
"""

"""
Question: 4303

Evidence: The paper content does not contain information on individuals who received protease inhibitors.

Rationale: The individuals are treatment-naïve, so they had not received any drug classes, including protease inhibitors.

Answer: No
"""

"""
Question: 4304

Evidence: The paper content does not contain information on individuals who received ART.

Rationale: The cohort is treatment-naïve, so the question of whether they all received the same ART is not applicable.

Answer: NA
"""

"""
Question: 4305

Evidence: The paper content does not contain information on individuals who received integrase inhibitors.

Rationale: As the individuals are treatment-naïve, they are, by definition, INSTI-naive.

Answer: Yes
"""

"""
Question: 4403

Evidence: The paper content does not contain information on individuals who received ART regimens.

Rationale: The cohort is treatment-naïve, so no individuals had received any ART regimens.

Answer: 0
"""

"""
Question: 4404

Evidence: The paper content does not contain information on individuals who received ART regimens.

Rationale: The cohort is treatment-naïve, so no individuals had received any ART regimens.

Answer: 0
"""

"""
Question: 4405

Evidence: The paper content does not contain information on individuals who received ART regimens.

Rationale: Since no individuals received ART, the question is not applicable.

Answer: NA
"""

"""
Question: 4406

Evidence: The paper content does not contain information on individuals who received ART regimens.

Rationale: Since the individuals are treatment-naïve, none of them received even one ART regimen.

Answer: No
"""

"""
Question: 4501

Evidence: The paper content does not contain information on individuals who received dolutegravir.

Rationale: The cohort is treatment-naïve, and dolutegravir is not mentioned in the paper.

Answer: 0
"""

"""
Question: 4502

Evidence: The paper content does not contain information on individuals who received darunavir.

Rationale: The cohort is treatment-naïve, and darunavir is not mentioned in the paper.

Answer: 0
"""

"""
Question: 5101

Evidence: The overall prevalence of TDRM was 14% (19/135).

Rationale: This sentence provides the total number of individuals found to have one or more drug resistance mutation.

Answer: 19
"""

"""
Question: 5102

Evidence: The paper content does not contain any mention of INSTI-resistance mutations.

Rationale: The reported resistance mutations are only for NRTIs, NNRTIs, and PIs. Integrase was not sequenced, and INSTI mutations are not discussed.

Answer: 0
"""

"""
Question: 5103

Evidence: The paper content does not contain a specific count of individuals with TDF-resistance mutations.

Rationale: While mutations like K65R that confer TDF resistance are mentioned in the context of the surveillance list, the paper does not report that any individuals in the cohort had a TDF-resistance mutation. The mutations found are listed in Table 2, and none are specifically noted as causing TDF resistance.

Answer: 0
"""

"""
Question: 5104

Evidence: The paper content does not contain any mention of INSTI-resistance mutations.

Rationale: The study did not sequence the integrase gene and therefore does not report any INSTI-resistance mutations.

Answer: NA
"""

"""
Question: 6101

Evidence: The paper content does not contain any mention of phenotypic susceptibility tests.

Rationale: The methods describe genotypic resistance testing and in silico prediction of susceptibility, but not laboratory-based phenotypic tests.

Answer: NA
"""

"""
Question: 6102

Evidence: The paper content does not contain any mention of IC50 or IC90 values.

Rationale: As phenotypic testing was not performed, no IC values are reported.

Answer: No
"""

"""
Question: 6103

Evidence: The paper content does not contain any mention of IC50 fold change values.

Rationale: As phenotypic testing was not performed, no fold change values are reported.

Answer: No
"""

"""
Question: 6104

Evidence: The paper content does not contain any mention of a phenotypic susceptibility assay.

Rationale: The paper does not use or report any phenotypic susceptibility assays.

Answer: NA
"""

"""
Question: 6105

Evidence: The paper content does not contain any mention of replication capacity.

Rationale: Replication capacity assays are not mentioned"""
Question: 6106

Evidence: The paper content does not contain any mention of phenotypic susceptibility testing for specific drugs.

Rationale: Since phenotypic susceptibility testing was not performed, no drugs were tested using this method. The paper only reports genotypic resistance predictions.

Answer: NA
"""

"""
Question: 7101

Evidence: The paper content does not contain any mention of site-directed mutagenesis.

Rationale: All sequences analyzed in the study were obtained from clinical isolates from infected children. There is no description of creating or studying site-directed mutants.

Answer: No
"""

"""
Question: 7102

Evidence: The paper content does not contain any mention of in vitro passage experiments.

Rationale: As established in question 1103, the study is based on clinical samples and sequence analysis, not on laboratory passage experiments.

Answer: No
"""